NTLA vs SLS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NTLA · Intellia Therapeutics$11.35 ▲ 2.25%
SLS · Sellas Life Sciences$8.42 ▲ 6.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NTLA +16.6%
- SLS +461.3%
Head to head
| Metric | NTLA | SLS |
|---|---|---|
| Price | $11.35 | $8.42 |
| Change today | ▲ 2.25% | ▲ 6.85% |
| Market cap | $1.59B | $1.70B |
| Return, 3 months | -5.6% | -23.7% |
| Return, year to date | +26.3% | +123.3% |
| Return, 1 year | +19.2% | +429.6% |
| P/E (TTM) | -3.4 | -38.3 |
| P/B | 2.6 | 12.3 |
| P/E percentile vs own 5y | 65th | 7th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -46.2% | – |
| Net profit growth (YoY) | -5.3% | -45.5% |
| Gross margin | – | – |
| Operating margin | -711.7% | – |
| Net margin | -672.2% | – |
| Return on equity | -55.4% | -39.6% |
| Analyst target vs. price | +75.4% | +256.3% |
| Analyst buy share | 46% | 100% |
| RSI (14) | 45 | 37 |
| 30-day volatility | 72.2% | 108.8% |
| Max drawdown, 1 year | -45.6% | -49.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLS is the largest of the group by market value.
- SLS has returned the most over the past year.
- SLS carries the lowest trailing P/E.
- NTLA has been the calmest stock over the last 30 days.